Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Special Drug Use Surveillance for Entresto Tablets (Chronic Heart Failure, CLCZ696B1401)

NCT04781881 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT04781881
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04781881 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Special Drug Use Surveillance for Entresto Tablets (Chronic Heart Failure, CLCZ696B1401)
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
March 4, 2021
Completion date
April 21, 2023
Enrollment
688 (actual)
Sites
121

Conditions

As the registry lists them; a condition with its own page is linked.

chronic heart failure